drugset / Trial / NCT06530784
Cryoablation Combined With PD-1 Antibody and Bevacizumab for Hepatocellular Carcinoma
NaSingle-groupOpen-labelTreatment
Summary
To explore the safety and efficacy of cryoablation combined with PD-1 antibody and bevacizumab for patients with hepatocellular carcinoma resistance to PD-1/L1 antibody.
Timeline
- Start
- 2024-07-31
- Primary completion
- 2025-12-31
- Completion
- 2026-05-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | 15 mg/kg | Intravenous |
| Subject | Tislelizumab | Monoclonal antibody | 200 mg | Intravenous |